Aerocrine: Cost Savings In Asthma Management When Using NIOX MINO(R)

Main Category: Respiratory / Asthma
Article Date: 15 Jan 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Aerocrine AB (STO:AERO) reports that the first heath economic study evaluating the effect of introducing measurements of exhaled NO in asthma management has been published.

The objective of the study was to assess the impact on direct costs for asthma management in Germany when NIOX MINO is purchased and used.

The study is based on an estimated future reimbursement of 32 Euro per exhaled NO test. The study shows that regular measurements of exhaled NO with NIOX MINO in asthma patients using inhaled corticosteroids result in a cost saving of 30 Euro per patient and year. In patients with more severe asthma, the use of NIOX MINO resulted in a cost saving of 160 Euro per patient and year.

The cost savings were achieved as a result of therapy being optimally adjusted based on NIOX MINO test results. Incorporating measurements of exhaled NO, the number of acute hospital visits was reduced and lower doses of anti-inflammatory medication were required to keep the patient's asthma controlled. The introduction of regular measurements of exhaled NO balances the costs incurred for the tests performed with NIOX MINO and generates a cost saving.

The article has been e-published ahead of print in Respiratory Medicine.

"The fact that exhaled NO measurements reduce the overall cost of therapy as well as dramatically improve airway disease management is of significant importance both for the patient and for the continued establishment of exhaled NO in clinical practice," says Paul de Potocki, CEO Aerocrine.

About Aerocrine

Aerocrine AB (publ) is a medical technology concern focused on the improved management and care of patients with airway inflammation. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. The company markets NIOX® Flex globally, and also markets NIOX MINO® - which represents a new generation of hand-held products - in Europe. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of asthma patients. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 8 am on January the 14th, 2008.

http://www.aerocrine.com/